An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).

被引：0
|
作者：
Hodi, F. Stephen
Baudelet, Christine
Chen, Allen C.
Weber, Jeffrey S.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Bristol Myers Squibb Co, Braine Lalleud, Belgium
[3] Bristol Myers Squibb Co, Princeton, NJ USA
[4] Lee Moffitt Canc Ctr, Tampa, FL USA
[5] Res Inst, Tampa, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9107
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL)
    Wolchok, Jedd D.
    Kluger, Harriet M.
    Callahan, Margaret K.
    Postow, Michael Andrew
    Gordon, Ruth Ann
    Segal, Neil Howard
    Rizvi, Naiyer A.
    Lesokhin, Alexander M.
    Reed, Kathleen
    Burke, Matthew M.
    Caldwell, Anne
    Kronenberg, Stephanie Anne
    Agunwamba, Blessing
    Feely, William
    Hong, Quan
    Horak, Christine E.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Combined nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab in the treatment of advanced melanoma (MEL) patients (pts): Safety and clinical activity
    Sznol, M.
    Callahan, M. K.
    Kluger, H.
    Postow, M. A.
    Burke, M.
    Hong, Q.
    Selby, M.
    Korman, A.
    Gupta, A.
    Wolchok, J. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S866 - S866
  • [3] Phase 2 study of nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in patients with advanced melanoma
    Yamazaki, N.
    Tahara, H.
    Uhara, H.
    Moroi, Y.
    Kiyohara, Y.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S868 - S868
  • [4] An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL)
    Sosman, Jeffrey Alan
    Martin-Algarra, Salvador
    Wolchok, Jedd D.
    Sharfman, William Howard
    Bhatia, Shailender
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Gajewski, Thomas
    Slingluff, Craig L.
    Kaufman, Howard
    Gupta, Manish
    McGirr, Analia
    Horak, Christine E.
    Ahlers, Christoph Matthias
    Wigginton, Jon M.
    Urba, Walter John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.
    Callahan, Margaret K.
    Bendell, Johanna C.
    Chan, Emily
    Morse, Michael
    Pillai, Rathi Narayana
    Bono, Petri
    Jaeger, Dirk
    Evans, T. R. Jeffry
    Chau, Ian
    Calvo, Emillano
    Le, Dung T.
    Ott, Patrick Alexander
    Taylor, Matthew Hiram
    Sharma, Padmanoo
    Antonia, Scott Joseph
    Sharkey, Brian
    Christensen, Olaf
    Amin, Asim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Phase 2 study of Nivolumab (Anti-PD-1; ONO-4538/BMS-936558) in Japanese patients with advanced melanoma: Preliminary report
    Yamazaki, N.
    Kiyohara, Y.
    Uhara, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S110 - S110
  • [7] A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
    Robert, Caroline
    Ascierto, Paolo Antonio
    Maio, Michele
    Hernberg, Micaela
    Schmidt, Henrik
    Waxman, Ian
    Garbe, Claus
    Lebbe, Celeste
    Hauschild, Axel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
    Hodi, F. Stephen
    Sznol, Mario
    Kluger, Harriet M.
    McDermott, David F.
    Carvajal, Richard D.
    Lawrence, Donald P.
    Topalian, Suzanne Louise
    Atkins, Michael B.
    Powderly, John D.
    Sharfman, William Howard
    Puzanov, Igor
    Smith, David C.
    Leming, Philip D.
    Lipson, Evan J.
    Taube, Janis M.
    Anders, Robert
    Horak, Christine E.
    Kollia, Georgia
    Gupta, Ashok Kumar
    Sosman, Jeffrey Alan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab.
    Callahan, Margaret K.
    Horak, Christine E.
    Curran, Michael A.
    Hollman, Travis
    Schaer, David A.
    Yuan, Jianda
    Lesokhin, Alexander M.
    Kitano, Shigehisa
    Hong, Quan
    Ariyan, Charlotte Eielson
    Busam, Klaus J.
    Feely, William
    Jure-Kunkel, Maria
    Grosso, Joseph
    Simon, Jason S.
    Korman, Alan J.
    Wigginton, Jon M.
    Gupta, Ashok Kumar
    Sznol, Mario
    Wolchok, Jedd D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Amin, Asirn
    Ernstoff, Marc S.
    Infante, Jeffrey R.
    Heng, Daniel Yick Chin
    Rini, Brian I.
    Plimack, Elizabeth R.
    McDermott, David F.
    Kollmannsberger, Christian K.
    Reaume, Martin Neil
    Spratlin, Jennifer L.
    Knox, Jennifer J.
    Voss, Martin Henner
    Pal, Sumanta Kumar
    Shen, Yuri
    Dhar, Arindarn
    Hammers, Hans J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345